Thermo Fisher Q2: Pharma And Biotech Gains Offset By Weak Academic And Gov't Markets

Group 1 - The company assigned a Buy rating to Thermo Fisher Scientific Inc. (NYSE: TMO) in October 2024, anticipating a market recovery in 2025 [1] - The overall market has shown some early signs of recovery but remains weak this year [1] - The company raised its position in TMO through stock ownership, options, or other derivatives [1]